CJC-1295

Modified Growth Hormone Releasing Hormone

Level C
CJC-1295

Editor: Dr. Jobby John, PharmD, FACA

Peptide Ledger review boards: Medical Review Board (Dr. Jobby John, PharmD, FACA; Dr. Richard Harris, MD, PharmD, MBA; Dr. Tracy Neal, MD; Dr. John Thoppil, MD; Dr. Natalie Kash, MD; Dr. Rahil Roopani, MD)Pharmacist Review Committee (Rachel Kuretich, PharmD, PharmD; Daniel Alonso, PharmD, PharmD; Christina Gunter, PharmD, PharmD; Patrick Gurley, PharmD, MS, PharmD, MS; Gyu-Hee Min, PharmD, PharmD)

Reviewed November 13, 2025

References are being re-verified against PubMed and will return with review dates.

C
Emerging Evidence
Preclinical and animal studies with limited human data

Preclinical and animal studies with limited human data

CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that has been modified to increase its half-life and stability. It stimulates the pituitary gland to release growth hormone in a pulsatile manner, mimicking the body's natural GH secretion patterns. It is being studied in the context of aging, body composition, and metabolism.

CJC-1295 binds to GHRH receptors in the anterior pituitary gland, triggering the release of growth hormone. The Drug Affinity Complex (DAC) modification extends its half-life to 6-8 days, providing sustained GH elevation. Researchers are studying its effects on:

  • Lean muscle mass
  • Fat metabolism
  • Bone density
  • Sleep quality
  • Recovery and tissue repair
  • IGF-1 levels

Generally well-tolerated. Common effects:

  • Mild injection site reactions
  • Transient flushing or headache
  • Water retention (mild)
  • Increased hunger
  • Numbness or tingling (rare)

Serious adverse events are uncommon but include potential for elevated prolactin or changes in glucose metabolism.

Contraindicated in:

  • Active malignancy or history of cancer
  • Diabetic retinopathy
  • Pregnancy and lactation
  • Hypersensitivity to CJC-1295 or excipients

Precautions:

  • Monitor IGF-1 levels
  • Use caution in diabetes
  • Assess pituitary function before use
  • Medical supervision required

⚠️ Important safety information above

Dosing considerations for clinicians

Dosing considerations are available to verified clinicians.

Sign in for clinician access

Coming to the Lake Hills Pharmacy pipeline.

Lake Hills Pharmacy is preparing peptide formulations in anticipation of regulatory guidance on compounded peptides. Planned strengths and dosing are shared with verified clinicians.

Sign in as a verified clinician to see planned strengths and dosing.

Contact us for more information

For Healthcare Providers

New to Lake Hills Pharmacy? Join our provider network. Lake Hills Pharmacy is preparing peptide programs as regulatory guidance on compounded peptides develops. Contact us for more information.

Contact us for more information

For Patients

Interested in CJC-1295? Connect with our medical team to discuss if this therapy is right for you.

or call us directly:

Clinical View: Complete drug monograph with evidence-based protocols. Switch to General View for patient-friendly information.

Important Information About Compounded Medications

These peptides are not FDA-approved but are commonly used by providers and patients under medical supervision. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. We provide evidence-based information from current research to help navigate this evolving field. Our goal is clear, evidence-based information for clinicians, with professional oversight at every step.

Lake Hills Pharmacy | Licensed 503A Compounding Pharmacy | Professional Medical Oversight Required